We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
-10.7%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.35B
AUM Growth
-$119M
Cap. Flow
-$74.1M
Cap. Flow %
-3.15%
Top 10 Hldgs %
36.4%
Holding
125
New
15
Increased
30
Reduced
16
Closed
20

Top Buys

Rank Stock Value
1
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$76.3M
2
AVXS
AveXis, Inc. Common Stock
AVXS
+$48.9M
3
EDIT icon
Editas Medicine
EDIT
+$44.9M
4
VTRS icon
Viatris
VTRS
+$37.5M
5
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$36M

Top Sells

Rank Stock Value
1
DYAX
DYAX CORPORATION
DYAX
+$84.3M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$53.5M
3
CRL icon
Charles River Laboratories
CRL
+$30.3M
4
GHDX
Genomic Health, Inc.
GHDX
+$28.5M
5
PCRX icon
Pacira BioSciences
PCRX
+$28.5M

Sector Composition

Rank Sector Weight
1 Healthcare 69.81%
2 Financials 4.2%
3 Technology 0.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HTWR
26
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
$27.4M 1.16%
870,634
+710,673
+444% +$24M
ACOR
27
DELISTED
Acorda Therapeutics
ACOR
$27.2M 1.16%
+8,578
New +$35.6M
DBVT
28
DBV Technologies
DBVT
$845M
$26.6M 1.13%
81,781
+35,594
+77% +$9.99M
RLYP
29
DELISTED
RELYPSA INC COM
RLYP
$25.4M 1.08%
1,873,471
+973,190
+108% +$16.5M
TVTY
30
DELISTED
Tivity Health, Inc. Common Stock
TVTY
$25M 1.06%
2,475,387
+10,345
+0.4% +$116K
INFI
31
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$23.2M 0.99%
4,398,862
+93,574
+2% +$573K
ZVRA icon
32
Zevra Therapeutics
ZVRA
$735M
$20.6M 0.88%
88,781
– –
LRMR icon
33
Larimar Therapeutics
LRMR
$391M
$20.4M 0.87%
254,634
+184,329
+262% +$14.6M
SRRA
34
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$20.2M 0.86%
75,033
+30,252
+68% +$9.66M
RAD
35
DELISTED
Rite Aid Corporation
RAD
$19.5M 0.83%
119,654
-4,985
-4% -$786K
GBT
36
DELISTED
Global Blood Therapeutics, Inc.
GBT
$18.9M 0.81%
1,193,811
+30,000
+3% +$533K
AXGN icon
37
Axogen
AXGN
$2.11B
$18.1M 0.77%
3,381,439
– –
AKTX
38
Akari Therapeutics
AKTX
$20.1M
$16.1M 0.69%
1,438
– –
ALPN
39
DELISTED
Alpine Immune Sciences Inc
ALPN
$15.6M 0.66%
933,103
– –
ELV icon
40
Elevance Health
ELV
$82.8B
$14.2M 0.6%
102,000
+87,351
+596% +$11.7M
LKFT
41
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.92B
$13.7M 0.58%
327,626
+144,626
+79% +$6.71M
NVAX icon
42
Novavax
NVAX
$1.31B
$12.7M 0.54%
+122,813
New +$13.2M
RGNX icon
43
Regenxbio
RGNX
$559M
$12.6M 0.54%
1,169,042
– –
IMPR
44
DELISTED
IMPRIVATA, INC COM
IMPR
$12.4M 0.53%
983,366
-223,052
-18% -$2.55M
CTMX icon
45
CytomX Therapeutics
CTMX
$790M
$12.2M 0.52%
943,433
-2,589
-0.3% -$36K
ALIM
46
DELISTED
Alimera Sciences
ALIM
$10.3M 0.44%
391,868
– –
TARA icon
47
Protara Therapeutics
TARA
$229M
$9.79M 0.42%
31,634
– –
MGNX icon
48
MacroGenics
MGNX
$280M
$9.71M 0.41%
517,920
– –
IVTY
49
DELISTED
Invuity, Inc
IVTY
$9.58M 0.41%
1,327,009
+248,791
+23% +$1.92M
GI
50
DELISTED
EndoChoice Holdings, Inc.
GI
$9.5M 0.4%
1,823,309
– –
1
2
3 4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q1 2016 Portfolio in Review

As of Q1 2016, Deerfield Management held 125 positions worth $2.35B, down 4.8% from $2.47B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Deerfield Management withdrew a net $74.1M in Q1 2016, closing 20 positions and reducing 16 holdings. Its most notable exit was DYAX CORPORATION, an estimated $84.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, up from 68% a quarter earlier, followed by Financials and Technology.

Against the trend, Deerfield Management opened a new position in AveXis, Inc. Common Stock worth $60.9M.

  • Deerfield Management's largest Q1 2016 buy was AveXis, Inc. Common Stock: 2,236,701 shares worth $60.9M.
  • Deerfield Management added most to Portola Pharmaceuticals, Inc. in Q1 2016, an estimated $76.3M increase.
  • Deerfield Management's biggest Q1 2016 reduction was Adeptus Health Inc, cutting an estimated $18.2M.
  • Deerfield Management fully exited DYAX CORPORATION in Q1 2016, selling an estimated $84.3M.
  • Deerfield Management's ten largest holdings make up 36% of its $2.35B portfolio in Q1 2016.
  • Deerfield Management opened 15 new positions and closed 20 in Q1 2016.
  • Deerfield Management's portfolio value fell 4.8% quarter-over-quarter to $2.35B.

Based on Deerfield Management's 13F filing for Q1 2016, filed 16 May 2016.